Recent news coverage primarily relates to broader market and commodity price movements, with no direct news on Adaptin Bio’s business activities. The company’s recent SEC filings and corporate actions provide the main insights into its status.

• Adaptin Bio’s common shares were approved for quotation on the OTCQB Venture Market under ticker APTN as of April 6, 2026 [S2].
• The company completed a private placement offering in December 2025, raising $1 million gross proceeds through sale of 200,000 shares at $5.00 per share, with related placement agent warrants and registration rights [S2].
• Executive employment agreements were amended in 2025 to increase time commitment and salaries for key officers, reflecting management stability and alignment [S2].
• Financial results for Q1 2026 show a net loss of $1,146,096 and basic EPS of -$0.13, with liquidity ratios indicating current liabilities exceed current assets significantly as of March 31, 2026 [S2].
• The company has no material pending legal proceedings as of the latest filings [S2].
• Research collaborations and patent license agreements with Duke University are in place, supporting the company’s biotechnology development efforts [S1].
• Recent broader market news includes commodity price changes and geopolitical developments but does not mention Adaptin Bio specifically [N1][N2][N3][N4][N5].

The company’s research collaborations and patent licenses with a reputable institution like Duke University provide a foundation for potential future product development. The private placement financing and equity incentive plans indicate ongoing capital support and management alignment. The company’s listing on the OTCQB Venture Market provides access to public capital markets. These factors support the company’s ability to advance its biotechnology programs and retain key personnel.

The company reported a net loss of over $1.1 million in Q1 2026 and has liquidity ratios indicating current liabilities significantly exceed current assets, which may constrain operational flexibility. As a smaller reporting company with no disclosed revenues, the company faces risks typical of early-stage biotechnology firms, including dependence on successful research outcomes, capital raising, and regulatory approvals. The absence of material pending legal proceedings reduces legal risk but does not mitigate operational and financial risks inherent in the business.

Adaptin Bio’s moat appears to be based on its intellectual property and research collaborations, including patent licenses and sponsored research agreements with Duke University. The company’s equity incentive plans and executive agreements suggest efforts to retain key talent. However, as a smaller reporting company with limited disclosed revenues and ongoing net losses, the company’s competitive advantages are primarily in its early-stage biotechnology assets and research partnerships rather than established market presence or cash flow generation.

• Liquidity Risk: As of March 31, 2026, Adaptin Bio’s current ratio was 0.28 and cash ratio was 0.12, indicating current liabilities substantially exceed current assets, which may limit the company’s ability to meet short-term obligations.
• Early-Stage Biotechnology Risk: The company operates in the biotechnology sector with ongoing research collaborations and patent licenses but has no disclosed revenues and reported net losses, reflecting typical risks of product development, regulatory approval, and commercialization.
• Capital Raising Risk: The company relies on private placements and public market access for funding. Failure to secure additional capital could impact its ability to continue operations and advance its programs.

• Adaptin Bio, Inc. is a publicly reporting company incorporated in Delaware with principal executive offices in Charlotte, North Carolina.
• The company’s common stock is quoted on the OTCQB Venture Market under the ticker symbol APTN as of April 6, 2026.
• As of June 11, 2026, the company had 8,903,229 shares of common stock issued and outstanding.
• Adaptin Bio is classified as a smaller reporting company and an emerging growth company, not a large accelerated filer or accelerated filer.
• The company has entered into multiple executive employment agreements with named officers, including amendments increasing time commitment and salary.
• Adaptin Bio completed a private placement offering on December 22, 2025, selling 200,000 shares of common stock at $5.00 per share for gross proceeds of $1.0 million, with related placement agent warrants and registration rights.
• The company has a 2025 Equity Incentive Plan and has granted options to executives subject to vesting and anti-dilution provisions.
• There are no material pending legal proceedings involving the company as of the latest filings.
• Financial snapshot as of March 31, 2026: cash and equivalents of $301,309; current assets of $706,117; current liabilities of $2,481,688; net loss of $1,146,096 for the quarter; basic EPS of -$0.13; diluted EPS reported as $0.13 (likely a reporting or classification note).
• Liquidity ratios as of March 31, 2026: current ratio of 0.28 and cash ratio of 0.12, indicating current liabilities significantly exceed current assets.
• The company files detailed SEC reports including 10-K/A and 10-Q with certifications by CEO and CFO.
• The company has agreements with Duke University for patent licenses and sponsored research, indicating a focus on biotechnology or related research.
• The company’s governance includes a board of directors with named individuals and executive officers.
• The company has agreed to use commercially reasonable efforts to keep registration statements effective for resale of shares issued in the private placement.
• Recent news items in the broader market include commodity price movements and geopolitical developments but do not directly mention Adaptin Bio’s operations or business model.